이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

DBS 이미징 기반 및 임계값 평가 기반 프로그래밍 (DBS-ITAP)

2026년 11월 6일 업데이트: Rob M.A. de Bie, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

파킨슨병에 대한 심뇌 자극의 임계값 평가 기반 프로그래밍과 영상 기반 프로그래밍을 비교하는 무작위 대조 시험

The goal of this single-center prospective, randomized, open-label clinical trial is to compare the effectiveness of imaging-based DBS programming with threshold assessment-based DBS programming in patients with Parkinson's disease and motor response fluctuations.

The main question the study aims to answer is:

Is the improvement of motor symptoms in the OFF-drug phase following STN DBS for Parkinson's disease, using imaging-based DBS programming only, non-inferior to the improvement of motor symptoms following DBS programming with threshold assessment at six months follow-up?

Participants will be randomized to imaging-based programming or to threshold assessment-based programming. The main clinical outcome is motor symptoms; secondary outcomes are level of physical disability and quality of life, among others.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

Rationale:

Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for disabling motor symptoms of Parkinson's disease (PD). Correct programming of DBS settings to provide optimal stimulation within the target region is crucial for a successful clinical outcome. To date, programming DBS settings is based on the selection of contact point(s) and stimulation parameters with standardized threshold assessments: for each contact point the current is increased in small steps and the severity of motor symptoms and possible adverse effects are assessed with each step. This process is challenging and time consuming because of the vast number of possible parameter combinations. Furthermore, individual variation in patient anatomy, placement of DBS leads and the occurrence of adverse effects must be considered. This results in long programming sessions that can be exhausting for patients and often leads to inconclusive results due to fatigue. Imaging techniques have been improved greatly over the years and could be useful for programming of DBS settings based on patient-specific anatomy.

Objective:

The aim of this study is to determine whether imaging-based DBS programming for the treatment of Parkinson's motor symptoms in STN DBS is non-inferior to the current standard practice of clinical threshold assessment-based DBS programming.

Study design:

The study is a single-center prospective, randomized, open-label, blinded end-point (PROBE design) clinical trial. Following surgery for DBS implantation, in total 132 patients will be randomized in a 1:1 ratio to initial imaging-based DBS programming (Imaging group) or to DBS programming based on initial threshold assessment (Threshold group). Follow-up is six months and consists of 3 study visits.

Study population:

Patients are eligible for the trial if they will have bilateral STN DBS for Parkinson motor symptoms at Amsterdam UMC.

Interventions:

In both groups (i.e., Imaging and Threshold), DBS programming will start two to three weeks after DBS surgery. For the DBS programming patients are admitted in the hospital for a day while they are off Parkinson medication.

Imaging group:

With the use imaging investigators are capable to visualize the location of the DBS lead within the individual's segmented anatomy and volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function), this may have the potential to improve programming of the stimulation parameters and outcomes. For this, the postoperative CT-scan is used to localize the DBS leads and the surrounding anatomic structures are reconstructed with the patient's preoperative MRI scan. Based on the patient-specific anatomy the DBS settings (appropriate contacts, amplitude, and pulse width) can be determined that produce the ideal VTA within the target and minimalizing stimulation of the surrounding structures. These settings can then be used as starting point for the programming of the stimulation parameters.

Threshold group:

Each DBS-electrode has four to 16 contact points, close to the tip, from where electrical current can be emitted. When programming DBS, the contact point or combination of contact points used for stimulation and the optimal electrical stimulation parameters are chosen. Two to three weeks after the surgery the clinician turns on the DBS. For this purpose, the patient is admitted to the hospital, and the initial threshold assessment is performed for each contact point. A crucial step in this process is to determine for each separate contact point, the amount of current needed to generate symptomatic improvement and the amount of current that generates adverse effects. To determine these thresholds, current is increased with 0.5 milliampere (mA) steps from 0 to approximately 5.0 mA, sequentially for each contact point, and the severity of Parkinson symptoms and possible adverse effects are assessed with each step. For this threshold-assessment, patients have to be off Parkinson medication (OFF-drug phase). Based on the threshold-assessments the active contact point(s) and stimulation parameters are selected. The DBS current is usually gradually increased over weeks to months with corresponding adjustments of the pharmacological treatment. For patients with bilateral DBS and four contact points on each electrode, the threshold-assessment takes about three hours.

The patient has a 50% chance of being randomized to initial imaging-based DBS programming (i.e., Imaging group). The expected benefit for this group is that they will not need the threshold-assessment and therefore have less burden due to less hospital visits for the programming. There are no extra risks associated with participation in this study. If the stimulation parameters found with imaging-based programming only do not yield enough effect in the Imaging group, the healthcare professionals can choose to execute the threshold-assessment for these patients.

Impact:

The results of the study may well contribute to reducing the burden of DBS treatment. If imaging-based programming is non-inferior to threshold assessment-based programming, this may result in more efficient programming sessions with reduced programming time (less use of health-care resources) and less discomfort for patients.

연구 유형

중재적

등록 (실제)

132

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • North Holland
      • Amsterdam, North Holland, 네덜란드, 1105 AZ
        • Amsterdam UMC location AMC

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Parkinson's disease diagnosis based on the clinical diagnostic criteria of Movement Disorder Society
  • Scheduled for DBS screening
  • Age of 18 years or older
  • Understand the Dutch language

Exclusion Criteria:

  • Legally incompetent adults
  • No written informed consent
  • Previous functional stereotactic neurosurgery
  • Dementia
  • Current depression or psychosis

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Imaging-based

66 patients with Parkinson's disease will receive imaging-based DBS programming

Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.

활성 비교기: Threshold assessment-based

66 patients with Parkinson's disease will receive DBS programming based on the threshold assessment

The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III in OFF phase
기간: Change from baseline to 6 months of DBS.

The MDS-UPDRS III measures severity of Parkinson's disease. The scores range between 0 - 132, higher scores indicating worse motor symptoms.

Change from baseline to 6 months of DBS.

2차 결과 측정

결과 측정
측정값 설명
기간
MDS-UPDRS III in ON phase
기간: Change from baseline to 6 months of DBS.

The MDS-UPDRS III measures severity of Parkinson's disease. The scores range between 0 - 132, higher scores indicating worse motor symptoms.

Change from baseline to 6 months of DBS.
MDS-UPDRS IV
기간: Change from baseline to 6 months of DBS.

Part IV of the MDS-UPDRS evaluates two motor complications: dyskinesia duration and severity and motor fluctuations by means of six questions administered by a healthcare professional. The fourth part ranges from 0 to 24, with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
MDS-UPDRS I
기간: Change from baseline to 6 months of DBS.

Part I of the MDS-UPDRS evaluates the non-motor impact on patients' experiences of daily living by means of questions administered by a healthcare professional and self-administered questions. The first part ranges from 0 to 52, with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
MDS-UPDRS II in ON phase
기간: Change from baseline to 6 months of DBS.

Part II of the MDS-UPDRS evaluates motor experiences in daily living by means of a self-administered questionnaire. The second part ranges from 0 to 52 with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
Academic Medical Center Linear Disability Score (ALDS)
기간: Change from baseline to 6 months of DBS.

The ALDS measures the disability status of patients with a broad range of diseases. It is expressed by the ability to perform activities in daily living and each item is scored separately. The scores range between 0 - 100, lower scores indicating more disability.

Change from baseline to 6 months of DBS.
Parkinson's Disease Questionnaire 39 (PDQ-39)
기간: Change from baseline to 6 months of DBS.

The PDQ-39 evaluates the quality of life by means of a questionnaire containing 39 items and eight dimensions (i.e., mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort). The total score is the sum of the eight different dimensions and yields a score between 0 and 100. A higher score indicates less quality of life.

Change from baseline to 6 months of DBS.
Patient satisfaction of the outcome of treatment
기간: At 6 months of DBS

The degree of satisfaction scored by the patient on a 5-point Likert scale, with higher scores indicating higher experienced satisfaction.

At 6 months of DBS
Patient evaluation of the burden of therapy
기간: At 6 months of DBS

The degree of experienced burden scored by the patient on a 5-point Likert scale, with higher scores indicating higher experienced burden.

At 6 months of DBS
Adverse effects
기간: At 6 months of DBS

Number and sort of adverse effects observed during six months follow-up after DBS.

At 6 months of DBS
Use of care
기간: At 6 months of DBS

Total contact moments (via telephone or in hospital) during six months follow-up after DBS.

At 6 months of DBS
Total duration of programming sessions
기간: At 6 months of DBS

Combined duration of programming sessions during the follow-up period after DBS.

At 6 months of DBS
Final DBS settings
기간: At 6 months of DBS

Final stimulation parameters at 6 months after follow-up.

At 6 months of DBS

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Rob de Bie, Prof, Amsterdam UMC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 1월 3일

기본 완료 (실제)

2026년 10월 19일

연구 완료 (실제)

2026년 10월 19일

연구 등록 날짜

최초 제출

2024년 1월 2일

QC 기준을 충족하는 최초 제출

2024년 1월 23일

처음 게시됨 (실제)

2024년 1월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NL84601.018.23

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All individual participant data that underlie results in the publication will be made available

IPD 공유 기간

It will be made available one year after the last study visit of the last participant

IPD 공유 액세스 기준

Upon request

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .